Sim, H.-W., Lwin, Z., Barnes, E., McDonald, K., Koh, E.-S., Rosenthal, M., … Khasraw, M. (2022). GENOME-WIDE DNA METHYLATION PATTERNS IN VERTU: A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY AND TEMOZOLOMIDE IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA. In Neuro Oncology (Vol. 24, pp. 81–81).

Sim, Hao-Wen, Zarnie Lwin, Elizabeth Barnes, Kerrie McDonald, Eng-Siew Koh, Mark Rosenthal, Matthew Foote, et al. “GENOME-WIDE DNA METHYLATION PATTERNS IN VERTU: A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY AND TEMOZOLOMIDE IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA.” In Neuro Oncology, 24:81–81, 2022.

Sim H-W, Lwin Z, Barnes E, McDonald K, Koh E-S, Rosenthal M, et al. GENOME-WIDE DNA METHYLATION PATTERNS IN VERTU: A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY AND TEMOZOLOMIDE IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA. In: Neuro Oncology. 2022. p. 81–81.

Sim, Hao-Wen, et al. “GENOME-WIDE DNA METHYLATION PATTERNS IN VERTU: A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY AND TEMOZOLOMIDE IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA.” Neuro Oncology, vol. 24, 2022, pp. 81–81.

Sim H-W, Lwin Z, Barnes E, McDonald K, Koh E-S, Rosenthal M, Foote M, Back M, Wheeler H, Buckland M, Walsh K, Fisher L, Leonard R, Hall M, Ashley D, Yip S, Simes J, Sulman E, Khasraw M. GENOME-WIDE DNA METHYLATION PATTERNS IN VERTU: A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY AND TEMOZOLOMIDE IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA. Neuro Oncology. 2022. p. 81–81.